Search Results
Long-term follow-up of luspatercept: response duration and progression to AML
Overall survival of patients following treatment with luspatercept in the MEDALIST trial
MEDALIST: OS & risk of disease progression in patients with MDS treated with luspatercept
Luspatercept compared with other available therapies for MF
Update on the COMMANDS trial: luspatercept is superior to ESA-based therapy in LR-MDS
Dr. Patel on the Clinical Implications of Luspatercept Approval in MDS
Improving the treatment of low-risk MDS: luspatercept, treatment sequencing & disease classification
The COMMANDS study: luspatercept versus epoetin alfa for ESA-naïve lower-risk MDS-associated anemia
MEDALIST: luspatercept and erythropoiesis biomarkers in MDS
The promise of luspatercept for the treatment of lower-risk MDS
Phase III INDEPENDENCE trial of luspatercept in patients with TD myelofibrosis on JAKi therapy
Does Luspatercept reduce blood transfusions in MDS patients?
